MedTrace Logo

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

NCT00189917 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-01-10

No results posted yet for this study

Summary

The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders.

Conditions

  • Dermatitis, Atopic
  • Hay Fever

Interventions

BIOLOGICAL

IMVAMUNE (MVA-BN)

1x10E08 TCID50, subcutaneous vaccination

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Bavarian Nordic

    lead INDUSTRY

Principal Investigators

  • Frank von Sonnenburg, M.D. · Department of Infectious Diseases and Tropical Medicine of the University of Munich

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2005-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189917 on ClinicalTrials.gov